SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is trending as investors prepare for a critical FDA advisory committee meeting on July 29 regarding deramiocel, a treatment for Duchenne muscular dystrophy. The community is focused on the potential for a dual-label approval for both skeletal and cardiac function, while actively debating the impact of recent briefing documentation and high short interest on the stock's near-term volatility.

D-Wave Quantum, Inc. engages in the development and delivery of quantum computing systems, software, and services. It provides customers with access to the company’s quantum computing systems via the cloud in the form of quantum computing as a service. It offers professional services such as customer assistance in identifying and implementing quantum-computing applications. The company was founded on January 25, 2022 and is headquartered in Palo Alto, CA.

D-Wave Quantum Inc

D-Wave Quantum is trending as investors react to a recent grant from the National Science Foundation, which bolsters the company's long-term fault-tolerant computing goals and strategic standing. While some community members remain optimistic about future contract potential and national security positioning, others are voicing concerns over recent insider share sales and the volatility typical of this high-growth sector.

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

Critical Metals Corp is trending following mixed sentiment regarding a retracted Kenya tender announcement and ongoing discussions about the company's Tanbreez project valuation. While some investors remain bullish on the long-term strategic importance of its heavy rare earth assets, others express frustration over share price volatility, management execution, and perceived lack of transparency.

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

Rigetti Computing is trending as investors react to new federal executive orders aimed at accelerating domestic quantum technology leadership and secure data migration. The community is actively debating the stock's long-term potential versus concerns over cash burn rates, insider selling, and the reliability of government-linked catalysts.

Omeros Corp. operates as a biopharmaceutical company, which engages in the research, discovery, development, and commercialization of small-molecule and protein therapeutics targeting immunologic diseases. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros Corp is trending as investors react to a negative opinion from the CHMP regarding the marketing authorization of Yartemlea in Europe, prompting the company to initiate an appeal through an Ad Hoc Expert Group. While community members are expressing significant frustration over regulatory hurdles and management's communication, many remain bullish on the company's US outlook, citing upcoming J-code implementation and a potential $100 million milestone payment as primary catalysts.

Bloom Energy Corp. engages in the manufacture and installation of a solid oxide fuel-cell based power generation platform. Its product, Bloom Energy Server, converts standard low-pressure natural gas or biogas into electricity through an electrochemical process without combustion. The company was founded by K. R. Sridhar, John Finn, Jim McElroy, Matthias Gottmann, and Dien Nguyen on January 18, 2001, and is headquartered in San Jose, CA.

Bloom Energy Corp - Ordinary Shares - Class A

Bloom Energy is currently trending as investors debate whether the recent double-digit volatility represents a massive buying opportunity ahead of upcoming earnings or a fundamental shift in the stock's valuation. While community sentiment is heavily polarized between long-term bulls highlighting strong AI data center backlog demand and aggressive short-sellers citing supply chain concerns, the stock remains a primary focus for traders watching institutional options flow and technical support levels.

Litecoin is a decentralized, peer-to-peer digital currency designed to enable instant, near-zero cost payments to individuals and merchants worldwide. As an open-source global payment network that functions independently of central banks or intermediaries, its main value proposition lies in providing a scarce digital asset with a fixed maximum supply of 84 million tokens.  The network operates using a Proof of Work mechanism where computers solve complex puzzles to confirm transactions and secure the blockchain. It is distinguished by a block generation time of 2.5 minutes, which allows for faster transaction confirmations and a higher total throughput than earlier protocols. Key technical features include the Scrypt hashing algorithm, which promotes wider network participation, and MimbleWimble Extension Blocks, which improve user privacy by allowing transaction details to be hidden.  The LTC token is used for settling global payments, executing microtransactions through smaller units called litoshis, and diversifying digital portfolios with a highly liquid asset. New tokens are issued to miners as rewards for verifying blocks, though these rewards undergo a halving event approximately every four years to strictly control inflation. This process ensures the ledger maintains immutability, meaning records cannot be changed once they are saved to the global network.  Created by former Google engineer Charlie Lee, the project is supported by the Litecoin Foundation, a non-profit organization dedicated to ecosystem adoption. Unlike many venture-backed projects, it is maintained by a decentralized community of independent developers and a global network of miners. The project has seen recent institutional adoption, with entities like Lite Strategy and Luxxfolio Holdings adding significant amounts of LTC to their corporate treasuries as of late 2025.

Litecoin

Litecoin is trending as investors debate whether the asset is finally carving out a macro bottom, fueled by technical signals like potential head-and-shoulders formations and bullish chart indicators. The community remains deeply divided, with many users highlighting increasing merchant adoption and institutional custody integration while others express frustration over stagnant price action and persistent market skepticism.

ProShares Trust II - ProShares UltraShort Bloomberg Crude Oil -2x Shares

ProShares UltraShort Bloomberg Crude Oil

The community is actively debating the future of crude oil prices amid geopolitical tension, with many traders using SCO as a tactical vehicle to hedge against ongoing supply disruptions in the Strait of Hormuz. Sentiment remains highly divided between those betting on a swift diplomatic resolution that would trigger a rapid decline in oil prices and others concerned that persistent supply constraints and futures market decay will continue to pressure the fund's performance.

Legend Biotech Corp. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, manufacturing, and commercialization of novel therapies for oncology and other indications. The firm develops advanced cell therapies across a diverse array of technology platforms, including autologous and allogeneic chimeric antigen receptor T-cell, gamma-delta T cell and natural killer cell-based immunotherapy. It operates through the following geographical segments: United States of America, China, and Other. The company was founded in 2014 and is headquartered in Somerset, NJ.

Legend Biotech Corp - ADR

Legend Biotech

Legend Biotech is facing significant downward pressure following leadership changes as CEO Ying Huang steps down, fueling investor uncertainty regarding strategic continuity during a critical growth phase. While some market participants see the current volatility as an overreaction to the transition and potential competitive shifts in the multiple myeloma space, others remain cautious until the company provides further clarity on its long-term commercial execution and in-vivo pipeline potential.

Anthropic

Anthropic is currently in the spotlight due to high-stakes infrastructure deals and aggressive fundraising efforts, including multi-billion dollar partnerships with major tech giants that underscore the intense race for compute capacity. Community discussion is heavily focused on the company's path toward a potential IPO, its evolving competitive stance against OpenAI, and concerns surrounding the sustainability of the massive capital expenditures driving current AI growth.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Kyverna Therapeutics vs. Vertex Pharmaceuticals: Which Drug Developer Stock Is a Better Buy in 2026?

Key PointsKyverna Therapeutics is a clinical-stage biopharmaceutical firm advancing cell therapies for autoimmune diseases...

Kyverna Therapeutics Names Greg Martini CFO

(RTTNews) - Kyverna Therapeutics, Inc. (KYTX), Monday announced the appointment of Greg Martini as Chief Financial Officer, effective May 18...

Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Shares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX - Get Free Report) have received an average rating of 'Moderate Buy' from the five research firms that are covering the company, Marketbeat Ratings...

Kyverna Therapeutics (KYTX) to Release Earnings on Tuesday

Kyverna Therapeutics (NASDAQ:KYTX) will be releasing its Q1 2026 earnings before the market opens on Tuesday, May 12. (View Earnings Report at...

AIGH Capital Management LLC Acquires Shares of 1,500,000 Kyverna Therapeutics, Inc. $KYTX

AIGH Capital Management LLC purchased a new stake in shares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 1,500,000 shares of the company's stock, valued at approximately...

Kyverna Therapeutics Showcases miv-cel Data in SPS, gMG; CEO Eyes First Autoimmune CAR-T BLA

Kyverna Therapeutics (NASDAQ:KYTX) highlighted new clinical data for its CD19-directed autologous CAR T-cell therapy mivocabtagene autoleucel (miv-cel), formerly KYV-101, during an American Academy of Neurology (AAN) conference call focused on stiff person syndrome (SPS) and generalized myasthenia g...

Peapod Lane Capital LLC Decreases Holdings in Kyverna Therapeutics, Inc. $KYTX

Peapod Lane Capital LLC decreased its position in Kyverna Therapeutics, Inc. (NASDAQ:KYTX - Free Report) by 42.3% during the 4th quarter, according to its most recent disclosure with the SEC. The...

Kyverna Therapeutics' (KYTX) "Buy" Rating Reiterated at HC Wainwright

HC Wainwright restated a "buy" rating and set a $20.00 price target on shares of Kyverna Therapeutics in a research note on Thursday...

Kyverna Therapeutics (NASDAQ:KYTX) Shares Gap Up   - Should You Buy?

Kyverna Therapeutics (NASDAQ:KYTX) Shares Gap Up - Should You Buy...

Why Kyverna Therapeutics Shares Are Trading Higher By Over 25%; Here Are 20 Stocks Moving Premarket

Kyverna Therapeutics Inc (NASDAQ: KYTX) shares rose 25.8% in pre-market trading after positive trial results for miv-cel. Other gainers include HCAI, ELPW, and ALP.read more...

Kyverna Therapeutics, Inc. is a cell therapy clinical-stage biotechnology company, which engages in the provision of treatments and potential cures for serious autoimmune diseases. The company was founded in June 2018 and is headquartered in Emeryville, CA.

Kyverna Therapeutics Inc.

Dow, Nasdaq, S&P 500 Futures Edge Higher After Trump Extends Iran Ceasefire: POET, NVTS, KYTX, TSLA Stocks Garner Focus Today

Equity

Neutral Sentiment

U.S. - Iran negotiations

Earnings

FOMC meeting

Other (drop a comment)

This week brings a Federal Reserve rate decision, Q2 GDP and PCE inflation data, and earnings from $MSFT, $META, $AAPL, and $AMZN. What will be the biggest driver of the market this week? Vote and explain your reasoning in the comments.

What will be the main driver of the market this week? 
 
Explain your reasoning in the comments.

Feed

News

Sentiment

Earnings

Fundamentals

Info

KYTXKyverna Therapeutics Inc.

Fundamentals

Latest KYTX News